keyboard_arrow_up

Regenerative Medicine and Stem Cells Partnering Terms and Agreements ( Published Date » 2014-03-03 No. Of Pages » 768)

ResearchMoz include new market research report" Regenerative Medicine and Stem Cells Partnering Terms and Agreements " to its huge collection of research reports.

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies.

 

  • Trends in regenerative medicine and stem cells deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for regenerative medicine and stem cells

 

The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements announced in the healthcare sector.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

                                

This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since 2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

For example, analyzing actual company deals and agreements allows assessment of the following:

 

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

The initial chapters of this report provide an orientation of drug dealmaking and business activities. 

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in regenerative medicine and stem cells dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in regenerative medicine and stem cells partnering and dealmaking since 2009.

 

In addition, a comprehensive appendix is provided organized by regenerative medicine and stem cells partnering company A-Z , deal type definitions and regenerative medicine and stem cells partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.

Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of regenerative medicine and stem cells deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
  • Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies
  • Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
  • Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Upcoming Reports:

DNA and RNA Probes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

By - Transparency Market Research

Single-stranded fragments of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are called DNA probes and RNA probes respectively.These DNA and RNA probes are short in length (usually 100-1000 bases long) capable of forming highly specific, non-covalent duplexes with complementary sequence of nucleic acid strand. Therefore typical applications of these probes are in (fluorescence) in situ hybridization ((F)ISH), microarray-based gene expression profiling or electrophoretic mobility shift assays (EMSA). These DNA and RNA genetic probes have three important...

Metal Matrix Composites Market - Global Industry Size, Share, Trends, Analysis and Forecasts, 2012 - 2018

By - Transparency Market Research

A composite material with at least two parts one being metal and other compound may be ceramic, organic material or another metal is called a metal matrix composite. Metal matrix composites can be manufactured by three main types: solid, liquid and gaseous. Metal matrix composites are widely used in ground transportation, electronics, aerospace, industrial use, construction and in consumer products.  The major factors which are driving the metal matrix composites market include: the growth of construction and civil engineering industry and their easy adoption rate due...

Full Body Scanners Market - Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2011 - 2018

By - Transparency Market Research

A full-body scanner is a specialized device which is capable of seeing through clothes and walls by creating the image of a person’s naked body without making any kind of physical contact or physically removing their clothes. Technology used in the scanner is a millimeter wave technology which is mainly responsible to see through the body. The device in active form reflects radio waves of high frequency off the body and generates an image which enables to spot some types of objects hidden under the clothes or under any kind of cover. This technology is gaining popularity as...

About ResearchMoz  

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

Website@ http://www.researchmoz.us/

Email: sales@researchmoz.us

Browse Blog - http://pramoddige91.wordpress.com/